CANTI

Find the evidence worth discussing.

CANTI organizes structured evidence for clinician discussion. It does not provide medical advice or care-planning guidance.

Glioblastoma GBM Melanoma Lung cancer EGFR MGMT Temozolomide Clinical trials

Live structured evidence · Requires oncology review · Evidence lists updated May 16, 2026

Open the interactive evidence map

Use the interactive dashboard to cross-filter diseases, targets, drugs, trials, and signals. Select cards of interest and follow the source-backed links.

Open interactive dashboard Browse diseases Search targets

Disease context

Start from indexed disease hubs and follow source-backed context.

Browse diseases

Marker / target

Review target symbols, aliases, and linked evidence rows.

Browse targets

Drug / trial signal

Scan indexed drug records, trials, and target-linked research signals.

Browse drugs

Overview

Charts and summaries below reflect list reads as of May 16, 2026 (UTC), when available from the configured data source.

Data: Live structured evidence (Supabase)

Current database coverage

Public scan count — live source mix from a bounded anon read (max 10,000 rows per table). Indexed catalogue count — from catalog_source_stats when listed (e.g. ChEMBL molecules). Exact admin count — full table / per-source totals on /admin (service role).

drugs

chembl: 10,000+ in public scan · 16,738 indexed (catalogue stats)

drug_targets

chembl: 10,000+ in public scan (bounded view)

disease_drug_evidence

repodb: 4,857 in public scan · clinicaltrials.gov: 354 in public scan

disease_target_evidence

opentargets: 6,283 in public scan · dev_seed: 1 in public scan

drug_repurposing_signals

canti_signal_builder: 501 in public scan · dev_seed: 1 in public scan

clinical_trials

clinicaltrials.gov: 542 in public scan · dev_seed: 1 in public scan

Public scan count: first 10,000 rows per table (responsive cap). Totals at the cap are a lower bound, not an outage — see indexed catalogue stats below when available, or /admin for exact service-role counts.

MVP evidence path

Planned, foundation, and active integrations — ChEMBL and ClinicalTrials.gov use CLI batch jobs; other registry APIs remain planned.

ChEMBLactive

What measurable ligand–target relationships exist for this compound or close analogs? (Phase 4A: CLI enrichment into identifiers + mechanism-backed targets.)

ClinicalTrials.govfoundation

Where is this marker or drug represented in registered interventional or observational studies? (Phase 5A: v2 REST client + `npm run enrich:clinicaltrials` upserts `clinical_trials` and optional `disease_drug_evidence`.)

Open Targetsfoundation

What target–disease association and datatype-level evidence does Open Targets expose for a resolved pair? (Phase 6A: GraphQL client + `npm run enrich:opentargets` → `disease_target_evidence`; Phase 6B: controlled sample + operator SQL verification on configured hosts.)

repoDB-style repositioning evidencefoundation

Which source-backed disease–drug pair rows (approved-elsewhere / failed-in-dataset style labels) exist for import? (Phase 7A: local TSV/CSV CLI `npm run import:repodb` → `disease_drug_evidence` with `source = repodb`.)

RxNormplanned

Which RxCUI or synonym maps apply so rows from different feeds collapse safely?

Reference / audit dataset later

Power BI CSV import is paused; importer remains for post-hoc comparison.

Power BI export (reference)reference

Real import paused for MVP sequencing; importer + runbook kept for audit comparison.

Optional: PubChem (optional) — Optional MVP lane; adds breadth, not a substitute for ChEMBL activity curation.

Limitations & build flags

Read-only structured navigator
No clinical outcome benefit inferred
Trial presence does not imply success
Drug identity may require normalization
Terminated/withdrawn trials must remain visible

Research-only disclaimer

CANTI is a read-only structured evidence navigator for families, caregivers, and clinicians exploring oncology markers. Surfaces are source-backed evidence, target-linked research signals, and trial-matched options for discussion with your care team—not medical advice, not dose planning, and not care directives. An optional AI-assisted explanation (beta) on the Signals view summarizes structured fields only when operators enable it server-side; it is still not medical advice. Self-service genomic upload is not available on public routes; private analysis intake is operator-assisted. Every view requires oncology review before operational use.

Start with tumor markers

Guided evidence walks disease context and comma-separated markers into grouped, source-backed cards for oncology review — no chat, no file upload, not care-planning guidance.

Open guided flow

Target index

Curated targets

1481

Markers returned by the live targets aggregation.

Signal queue

Active research signals

500

Emerging or watchlisted themes from curated sources.

Source landscape

Evidence sources indexed

Appears in source landscape coverage for returned target rows.

Traceability

Dataset link coverage

86%

Share of entities with cross-reference links in dataset.

Target landscape

Guided cards — dense tables live on Targets.

Browse targets

5_8S_rRNA

5.8S ribosomal RNA

Find the evidence worth discussing.

Open the interactive evidence map

Disease context

Marker / target

Drug / trial signal

Drug-linked research signal cards